Company news

Cullinan Therapeutics, Inc. news in 2024

Cullinan Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

November 13, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 6, 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

November 4, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

November 3, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

October 15, 2024

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

September 16, 2024

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

September 15, 2024

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

September 13, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 7, 2024

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

May 31, 2024

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 22, 2024

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 14, 2024

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

April 28, 2024

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

April 23, 2024

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

April 15, 2024

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

April 15, 2024

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

February 29, 2024

Cullinan Oncology to Participate in Upcoming Investor Conferences

February 26, 2024

Decks in 2024